

해외 바이오의약품 임상 현황 (2020.06.22~2020.06.28)

한국바이오의약품협회, 2020.6.30.
출처: ClinicalTrials.gov

○ 미국 11건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04364178	Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV	Adenovirus[Cytomegalovirus Infections]Epstein-Barr Virus Infections	Biological: Adenovirus Specific T-Lymphocytes[Biological: Cytomegalovirus Specific T-Lymphocytes[Biological: Epstein-Barr Virus Specific T-Lymphocytes	Jessie Barnum University of Pittsburgh	Phase 1 Phase 2
NCT04438382	Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis	Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm[Steroid-Refractory Pneumonitis	Biological: Infliximab[Biological: Intravenous Immunoglobulin Therapy[Drug: Prednisone[Other: Quality-of-Life Assessment[Other: Questionnaire Administration	ECOG-ACRIN Cancer Research Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group	Phase 2
NCT04393350	Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer	Kidney Cancer[Stage III Renal Cell Cancer AJCC v8][Stage IV Renal Cell Cancer AJCC v8	Drug: Lenvatinib[Drug: Lenvatinib Mesylate[Biological: Pembrolizumab[Other: Quality-of-Life Assessment[Other: Questionnaire Administration	Emory University Merck Sharp & Dohme Corp.	Phase 2
NCT04343976	Pegylated Interferon Lambda Treatment for COVID-19	COVID-19[COVID	Drug: Pegylated interferon lambda	Raymond Chung Eiger BioPharmaceuticals Massachusetts General Hospital	Phase 2
NCT04253964	Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy	Nonsmall Cell Lung Cancer Performance Status	Drug: Pembrolizumab[Drug: Carboplatin[Drug: Paclitaxel[Drug: Nab paclitaxel[Other: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)][Other: QLQ-C30 Global Health/Quality of Life Questionnaire[Other: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes[Drug: Pemetrexed	Wake Forest University Health Sciences National Cancer Institute (NCI)	Phase 2
NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	Glioblastoma	Drug: INCMGA00012[Drug: INCAGN01876[Drug: SRS[Procedure: Brain surgery	University of Pennsylvania Incyte Corporation	Phase 2
NCT03846583	Tucatinib + Abemaciclib + Herceptin for HER2+ MBC	Breast Cancer	Drug: Tucatinib[Drug: Abemaciclib[Drug: Trastuzumab[Drug: Aromatase Inhibitor	Dana-Farber Cancer Institute Eli Lilly and Company	Phase 1
NCT04444752	A Study Assessing the Efficacy and Safety of CBP-201	Moderate-to-severe Atopic Dermatitis	Drug: CBP-201[Drug: placebo	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 2
NCT04437511	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	Alzheimer Disease	Drug: Donanemab[Drug: Placebo	Eli Lilly and Company	Phase 2
NCT04270747	A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]	Neovascular (Wet) Age-related Macular Degeneration (AMD)	Drug: ABP 938[Drug: Aflibercept	Amgen Parexel	Phase 3
NCT04450329	A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)	Neovascular Age-related Macular Degeneration	Drug: SB15 (Proposed aflibercept biosimilar)[Drug: Eylea (Aflibercept)	Samsung Bioepis Co., Ltd.	Phase 3
NCT03760575	Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)	Mesotheliomas Pleural	Drug: Pembrolizumab[Procedure: Indocyanine Green (ICG) Image-Guided Surgery[Drug: Cisplatin[Drug: Pemetrexed	Abramson Cancer Center of the University of Pennsylvania	Phase 1
NCT03203525	Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	Advanced Malignant Neoplasm[Colorectal Carcinoma Metastatic in the Liver[Metastatic Malignant Neoplasm in the Liver[Refractory Malignant Neoplasm	Biological: Bevacizumab[Drug: Fluorouracil[Drug: Leucovorin[Drug: Oxaliplatin[Drug: Pegylated Liposomal Doxorubicin Hydrochloride[Drug: Temsirolimus[Procedure: Tumor Treating Fields Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04205812	Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)	Metastatic Squamous Non-Small Cell Lung Cancer[Metastatic Nonsquamous Non-Small Cell Lung Cancer	Drug: Retifanlimab[Drug: Placebo[Drug: Pemetrexed[Drug: Cisplatin[Drug: Carboplatin[Drug: Paclitaxel[Drug: nab-Paclitaxel	Incyte Corporation Zai Lab (Shanghai) Co., Ltd.	Phase 3
NCT04338061	Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)	Relapsing Multiple Sclerosis	Drug: Evobrutinib[Drug: Placebo (match to Teriflunomide)[Drug: Teriflunomide[Drug: Placebo (match to Evobrutinib)	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany EMD Serono Research & Development Institute, Inc.	Phase 3
NCT04190628	Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors	Advanced Solid Tumor[BRAF V600 Mutation	Drug: ABM-1310	ABM Therapeutics, Inc.	Phase 1
NCT04442126	A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors	Advanced Solid Tumor	Biological: NM21-1480	Numab Therapeutics AG	Phase 1 Phase 2
NCT04382664	UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma	Malignant Melanoma	Biological: UV1[Biological: Sargramostim[Biological: Ipilimumab[Biological: Nivolumab	Ultimovacs ASA	Phase 2
NCT04398433	INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)	Respiratory Papillomatosis	Drug: INO-3107[Device: CELLECTRA™2000	Inovio Pharmaceuticals	Phase 1 Phase 2
NCT04440163	MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age	Meningococcal Vaccine	Biological: MenABCWY[Biological: Saline[Biological: Trumenb[Biological: MenACWY-CRM	Pfizer	Phase 3
NCT04440176	A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules	Meningococcal Vaccine	Biological: MenABCWY[Biological: Saline	Pfizer	Phase 2
NCT04424316	A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.	Respiratory Tract Infection	Biological: RSVpreF[Biological: Placebo	Pfizer	Phase 3
NCT04396236	A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Migraine	Drug: Lasmiditan[Drug: Placebo	Eli Lilly and Company	Phase 3
NCT04267822	Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV	RSV Infection[Stem Cell Transplant Complications][Lower Resp Tract Infection	Drug: RV521 oral tablet[Drug: Placebo oral tablet	ReViral Ltd	Phase 2
NCT04345367	Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Atopic Dermatitis	Drug: Abrocitinib 200 mg[Combination Product: Dupilumab 300 mg	Pfizer	Phase 3
NCT04095858	CD24Fc for the Prevention of Acute GVHD Following Myeloablative HSCT	Hematopoietic Stem Cell Transplantation[Acute Graft Versus Host Disease][Acute Myeloid Leukemia][Acute Lymphoblastic Leukemia][Myelodysplastic Syndromes	Drug: CD24Fc[Drug: Placebo[Drug: Methotrexate[Drug: Tacrolimus	Oncolmmune, Inc.	Phase 3

해외 바이오의약품 임상 현황 (2020.06.22~2020.06.28)

한국바이오의약품협회, 2020.6.30.
출처: ClinicalTrials.gov

NCT04404140	A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).	Castration-Resistant Prostatic Cancer	Drug: Ipatasertib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche	Phase 1
NCT04311710	A Study Evaluating the Drug Levels of Ipilimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types	Tumor	Drug: ipilimumab Drug: nivolumab Drug: ENHANZE (rHuPH20)	Bristol-Myers Squibb	Phase 1 Phase 2

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04235101	Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors	Solid Tumor	Drug: SYD985 + Niraparib	Byondis B.V.	Phase 1
NCT04307576	A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia	Leukemia, Acute Lymphoblastic	Drug: Omitted Doxorubicin Drug: Omitted Vincristine+Dexamethasone pulses Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy Drug: Imatinib	Mats Heyman The Swedish Research Council The Swedish Childhood Cancer Foundation Pfizer Servier NordForsk Aamu Pediatric Cancer Foundation Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany Clinical Trial Center North (CTC North GmbH & Co. KG) Belgium Health Care Knowledge Centre Karolinska Institutet Cancer Research UK Fundação Rui Osório de Castro Acreditar - Associação de Pais e Amigos das Crianças com Cancro Grupo Português De Leucemias Pediátricas Karolinska University Hospital	Phase 3

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04307576	A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia	Leukemia, Acute Lymphoblastic	Drug: Omitted Doxorubicin Drug: Omitted Vincristine+Dexamethasone pulses Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy Drug: Imatinib	Mats Heyman The Swedish Research Council The Swedish Childhood Cancer Foundation Pfizer Servier NordForsk Aamu Pediatric Cancer Foundation Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany Clinical Trial Center North (CTC North GmbH & Co. KG) Belgium Health Care Knowledge Centre Karolinska Institutet Cancer Research UK Fundação Rui Osório de Castro Acreditar - Associação de Pais e Amigos das Crianças com Cancro Grupo Português De Leucemias Pediátricas Karolinska University Hospital	Phase 3

○ 중국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04443543	An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer	Rectal Cancer	Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents Drug: irinotecan Radiation: IMRT Drug: Oxaliplatin Drug: 5Fluorouracil Drug: Tislelizumab	Fudan University	Phase 2
NCT04443296	Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma	Cervical Carcinoma	Drug: CCRT+TIL Drug: CCRT	Sun Yat-sen University	Phase 2
NCT04436133	Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolyomorpha)	HPV Infection HPV-Related Cervical Carcinoma	Biological: Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) Biological: 9-valent HPV vaccine (Gardasil 9)	National Vaccine and Serum Institute China Chengdu Institute of Biological Products Co.Ltd. Simoon Record Pharma Information Consulting Co.	Phase 2
NCT04325698	A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC	Advanced Non-squamous NSCLC	Drug: PF-06439535 (CN) Drug: Bevacizumab-EU Drug: Paclitaxel Drug: Carboplatin	Pfizer	Phase 3
NCT04444752	A Study Assessing the Efficacy and Safety of CBP-201	Moderate-to-severe Atopic Dermatitis	Drug: CBP-201 Drug: placebo	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 2

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04450329	A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)	Neovascular Age-related Macular Degeneration	Drug: SB15 (Proposed aflibercept biosimilar) Drug: Eylea (Aflibercept)	Samsung Bioepis Co., Ltd.	Phase 3
NCT04437511	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	Alzheimer Disease	Drug: Donanemab Drug: Placebo	Eli Lilly and Company	Phase 2